Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease

Cameron, Fiona; Altowati, Mabrouka; Rogers, P; McGrogan, Paraic; Anderson, Niall; Bisset, W M; Ahmed, S Faisal; Wilson, David C.; Russell, Richard K.

doi:10.1097/mpg.0000000000001379

Cited by 14 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the pivotal ADA trial, IFX-experienced patients were only half as likely to achieve disease remission during follow-up than IFX-naïve patients [ 5 ]. Secondly, the authors reported that younger age and shorter disease duration were associated with higher remission rates, a finding confirmed by several observational trials [ 18 , 22 – 24 ]. The third factor influencing remission rates in this trial was baseline C‐reactive protein (CRP).…”

Section: Optimising Treatmentmentioning

confidence: 65%

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Cozijnsen¹,

Samsom

Ridder³

2017

Pediatr Drugs

View full text Add to dashboard Cite

Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiveness has revealed potential markers, but data on their accuracy in paediatric CD patients are lagging behind. Also, new evidence has become available on the safety profile of anti-TNF antibodies that suggests the assumed increased malignancy risk seen in patients on anti-TNF and thiopurine combination treatment may be linked more to thiopurine use and not to anti-TNF treatment. In addition, the early results of CT-P13, an infliximab biosimilar, in CD patients confirm the expected similarity with its originator. Thus, the effectiveness of anti-TNF antibody treatment is slowly improving, its malignancy risk is lower than assumed, and its costs are reduced by the introduction of equally effective biosimilars. Together, these trends allow for a more prominent role for anti-TNF antibodies in future treatment of paediatric CD.

show abstract

Section: Optimising Treatmentmentioning

confidence: 65%

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Cozijnsen¹,

Samsom

Ridder³

2017

Pediatr Drugs

View full text Add to dashboard Cite

show abstract

“…It follows that the zero-differences of plasma TNF-α between children with and without OSAS might mirror inconsistencies as regards the definition of control samples. Fourth, Cameron et al [87] observed that besides the disease status, in pediatric samples with Inflammatory Bowel Disease, the outcome of an antitumor necrosis factor (TNF) therapy depended from participants' pubertal stage. Given this, it is conceivable that the zero-difference of plasma TNF-α between pediatric samples with and without OSAS might have been blurred by the pubertal stage.…”

Section: Discussionmentioning

confidence: 99%

Serum and Plasma Tumor Necrosis Factor Alpha Levels in Individuals with Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression

Imani

Sadeghi

Khazaie

et al. 2020

Life

View full text Add to dashboard Cite

Background: Obstructive sleep apnea syndrome (OSAS) is associated with a variety of inflammatory factors. Specifically, proinflammatory cytokines appear to be associated with the pathogenesis of OSAS. Methods: For the present meta-analysis and meta-regression on serum and plasma tumor necrosis factor alpha (TNF-α) levels in individuals with and without OSAS, we performed a systematic search without any restrictions of the PubMed/Medline, Scopus, Cochrane Library, and Web of Science databases to find relevant articles published up to 1 February 2020. Results: Fifty-five (adults: 29 studies on serum and 17 studies on plasma; children: 4 studies on serum and 5 studies on plasma) were included and analyzed. Always compared to age-matched healthy controls, the pooled MDs were as follows: adults, serum: 10.22 pg/mL (95% CI = 8.86, 11.58; p < 0.00001); adults, plasma: 5.90 pg/mL (95% CI = 4.00, 7.80; p < 0.00001); children, serum: 0.21 pg/mL (95% CI = 0.05, 0.37; p = 0.01); children, plasma: 5.90 pg/mL (95% CI = 4.00, 7.80; p < 0.00001). Conclusions: Compared to healthy and age-matched controls, adult individuals with OSAS had significantly higher serum/plasma TNF-α levels. For children with OSAS, significantly higher levels were observed for TNF-α in serum but not in plasma.

show abstract

“… 3 , 8 – 12 Furthermore, the extension to the REACH study (a randomized, multicenter, open-label study to evalu ate the safety and efficacy of anti-TNFα chimeric monoclonal antibody in pediatric subjects with moderate-to-severe Crohn’s disease) 13 and recent study by Cameron et al . 14 showed better growth improvement in patients under remission, suggesting difference in growth restoration depending on disease control status. Therefore, in order to investigate the long-term effect of combined immunosuppression on linear growth with exclusion of the influence of disease status, we aimed to investigate the impact of early combined immunosuppression on linear growth in pediatric CD patients who had continuously received combined immunosuppression with IFX and azathioprine (AZA) and had sustained remission for 3 years, by comparison with those who had stepped-up to receive combined immunosuppression and had sustained remission for 3 years.…”

Section: Introductionmentioning

confidence: 93%

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients

et al. 2018

View full text Add to dashboard Cite

Background/AimsInformation regarding the efficacy of early infliximab treatment in pediatric patients with Crohn’s disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons.MethodsThis retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups.ResultsThe early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1–2 (p=0.016).ConclusionsThe early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.

show abstract

Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease

Cited by 14 publications

References 46 publications

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Serum and Plasma Tumor Necrosis Factor Alpha Levels in Individuals with Obstructive Sleep Apnea Syndrome: A Meta-Analysis and Meta-Regression

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients

Contact Info

Product

Resources

About